Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Nucleic Acids Res ; 50(3): 1650-1660, 2022 02 22.
Artículo en Inglés | MEDLINE | ID: mdl-35051997

RESUMEN

The Cas9 nuclease from Staphylococcus aureus (SaCas9) holds great potential for use in gene therapy, and variants with increased fidelity have been engineered. However, we find that existing variants have not reached the greatest accuracy to discriminate base mismatches and exhibited much reduced activity when their mutations were grafted onto the KKH mutant of SaCas9 for editing an expanded set of DNA targets. We performed structure-guided combinatorial mutagenesis to re-engineer KKH-SaCas9 with enhanced accuracy. We uncover that introducing a Y239H mutation on KKH-SaCas9's REC domain substantially reduces off-target edits while retaining high on-target activity when added to a set of mutations on REC and RuvC domains that lessen its interactions with the target DNA strand. The Y239H mutation is modelled to have removed an interaction from the REC domain with the guide RNA backbone in the guide RNA-DNA heteroduplex structure. We further confirmed the greatly improved genome-wide editing accuracy and single-base mismatch discrimination of our engineered variants, named KKH-SaCas9-SAV1 and SAV2, in human cells. In addition to generating broadly useful KKH-SaCas9 variants with unprecedented accuracy, our findings demonstrate the feasibility for multi-domain combinatorial mutagenesis on SaCas9's DNA- and guide RNA- interacting residues to optimize its editing fidelity.


Asunto(s)
Proteína 9 Asociada a CRISPR/genética , Edición Génica , Staphylococcus aureus , Sistemas CRISPR-Cas , Humanos , Nucleasa Microcócica/genética , ARN Guía de Kinetoplastida , Staphylococcus aureus/genética
2.
Nat Methods ; 16(8): 789, 2019 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-31337886

RESUMEN

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

3.
Nat Methods ; 16(8): 722-730, 2019 08.
Artículo en Inglés | MEDLINE | ID: mdl-31308554

RESUMEN

The combined effect of multiple mutations on protein function is hard to predict; thus, the ability to functionally assess a vast number of protein sequence variants would be practically useful for protein engineering. Here we present a high-throughput platform that enables scalable assembly and parallel characterization of barcoded protein variants with combinatorial modifications. We demonstrate this platform, which we name CombiSEAL, by systematically characterizing a library of 948 combination mutants of the widely used Streptococcus pyogenes Cas9 (SpCas9) nuclease to optimize its genome-editing activity in human cells. The ease with which the editing activities of the pool of SpCas9 variants can be assessed at multiple on- and off-target sites accelerates the identification of optimized variants and facilitates the study of mutational epistasis. We successfully identify Opti-SpCas9, which possesses enhanced editing specificity without sacrificing potency and broad targeting range. This platform is broadly applicable for engineering proteins through combinatorial modifications en masse.


Asunto(s)
Proteína 9 Asociada a CRISPR/genética , Sistemas CRISPR-Cas/genética , Edición Génica , Mutagénesis , Mutación , ARN Guía de Kinetoplastida/genética , Programas Informáticos , Humanos , Ingeniería de Proteínas , Streptococcus pyogenes/enzimología , Especificidad por Sustrato
4.
Cell Rep ; 32(6): 108020, 2020 08 11.
Artículo en Inglés | MEDLINE | ID: mdl-32783942

RESUMEN

We present a CRISPR-based multi-gene knockout screening system and toolkits for extensible assembly of barcoded high-order combinatorial guide RNA libraries en masse. We apply this system for systematically identifying not only pairwise but also three-way synergistic therapeutic target combinations and successfully validate double- and triple-combination regimens for suppression of cancer cell growth and protection against Parkinson's disease-associated toxicity. This system overcomes the practical challenges of experimenting on a large number of high-order genetic and drug combinations and can be applied to uncover the rare synergistic interactions between druggable targets.


Asunto(s)
Sistemas CRISPR-Cas , Combinación de Medicamentos , Sistemas de Liberación de Medicamentos/métodos , Ensayos Analíticos de Alto Rendimiento/métodos , Animales , Antineoplásicos/farmacología , Drosophila melanogaster , Técnicas de Inactivación de Genes , Células HEK293 , Humanos , Ratones , Neoplasias/tratamiento farmacológico , Enfermedad de Parkinson/tratamiento farmacológico , ARN Guía de Kinetoplastida
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA